Crewe Advisors’s Definium Therapeutics DFTX Stock Holding History

Crewe Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$94K	Hold	1,999	–	–	0.01%	348
2026 Q1	$37.8K	Hold	1,999	–	–	﹤0.01%	402
2025 Q4	$26.8K	Hold	1,999	–	–	﹤0.01%	437
2025 Q3	$23.6K	Hold	1,999	–	–	﹤0.01%	467
2025 Q2	$13K	Hold	1,999	–	–	﹤0.01%	427
2025 Q1	$11.7K	Hold	1,999	–	–	﹤0.01%	414
2024 Q4	$13.9K	Hold	1,999	–	–	﹤0.01%	397
2024 Q3	$11.4K	Hold	1,999	–	–	﹤0.01%	473
2024 Q2	$14.4K	Hold	1,999	–	–	﹤0.01%	613
2024 Q1	$18.8K	Hold	1,999	–	–	﹤0.01%	505
2023 Q4	$7.32K	Hold	1,999	–	–	﹤0.01%	232
2023 Q3	$6.26K	Hold	1,999	–	–	﹤0.01%	277
2023 Q2	$7.14K	Hold	1,999	–	–	﹤0.01%	436
2023 Q1	$6.34K	Hold	1,999	–	–	﹤0.01%	610
2022 Q4	$4.4K	Hold	1,999	–	–	﹤0.01%	698
2022 Q3	$7K	Hold	1,999	–	–	﹤0.01%	768
2022 Q2	$19K	Buy	+1,999	New	+$25.3K	﹤0.01%	435

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Crewe Advisors's DFTX Position: Q2 2026 in Review

Crewe Advisors held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 1,999 shares worth $94K. The position accounts for 0.01% of the portfolio, ranked #348.

Crewe Advisors first reported a position in DFTX in Q2 2022 and has held it in 17 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Crewe Advisors held 1,999 shares of Definium Therapeutics worth $94K as of Q2 2026.
Crewe Advisors left its Definium Therapeutics share count unchanged in Q2 2026.
Definium Therapeutics made up 0.01% of Crewe Advisors's portfolio in Q2 2026, its #348 holding.
Crewe Advisors first reported a position in Definium Therapeutics in Q2 2022 and has held it in 17 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.